The U.K. is asking patients whose pancreas became dangerously inflamed after taking obesity drugs like Wegovy and Zepbound to ...

Cardiologists need to embrace the wave of new drugs, say experts, particularly since they can reduce the risk of CVD.

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...

Synthetic food dyes are added to 1 in 5 packaged foods and drinks sold by top U.S. food manufacturers, a new study says.

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Recent U.S. domestic news covers the FDA investigating deaths post-gene therapy by Sarepta, discussions at a CDC advisory ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...